5α-reductase inhibitors impact prognosis of urothelial carcinoma

5α-reductase inhibitors impact prognosis of urothelial carcinoma

Abstract Background 5α-reductase inhibitors (5-ARIs) inhibit the pathway of converting the testosterone to dihydrotestosterone and are widely used in benign prostatic hyperplasia patients. Since androgen receptor activation may play a role in urothelial tumorigenesis, we conducted this retrospective...

Full description

Bibliographic Details
Main Authors: Chien-Sheng Wang, Ching-Chia Li, Yung-Shun Juan, Wen-Jeng Wu, Hsiang-Ying Lee
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Cancer
Subjects:
5α-reductase inhibitors (5-ARIs)
Bladder cancer
Upper tract urothelial carcinoma
Androgen receptor (AR)
Finasteride
Dutasteride
Online Access:http://link.springer.com/article/10.1186/s12885-020-07373-4

Internet

http://link.springer.com/article/10.1186/s12885-020-07373-4

Similar Items